Internal Medicine
Partner With Us
Advertisement
Conexiant chevron_right Internal Medicine chevron_right Apixaban Lowers Bleeding Risk in HIV Patients With AF
From the Journals

Apixaban Lowers Bleeding Risk in HIV Patients With AF

In a national cohort study, warfarin and rivaroxaban were associated with significantly higher bleeding risks compared to apixaban in older adults with HIV and atrial fibrillation, particularly those on antiretroviral therapy.

Conexiant
article Full Article subject Summary summarize Notecard
  1. Apixaban may present a safer anticoagulation option compared to warfarin and rivaroxaban in older adults with HIV and atrial fibrillation.
  2. Warfarin users had a 2.6-fold increased major bleeding risk versus apixaban users.
  3. No significant differences in ischemic stroke or all-cause mortality rates were observed among the anticoagulants.
  4. Gastrointestinal bleeding risks were higher for warfarin and rivaroxaban.
  5. A considerable proportion of patients were not receiving antiretroviral therapy at the time of anticoagulant initiation, warranting further investigation.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.